文献速递甲状腺疾病

多发性硬化患者接受阿仑单抗后发生自身免疫性甲状腺疾病与治疗反应改善相关

Development of Autoimmune Thyroid Disease in Multiple Sclerosis Patients Post-Alemtuzumab Improves Treatment Response.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

回顾性分析2012至2017年一家三级转诊中心126例接受阿仑单抗治疗的复发缓解型多发性硬化患者,26%发生自身免疫性甲状腺疾病(AITD),其中55%为Graves病。发生AITD者扩展残疾状态量表评分较未发生者降低,且无复发生存率更高。

要点

  • 126例接受阿仑单抗治疗的多发性硬化患者中26%发生自身免疫性甲状腺疾病。
  • 发生的自身免疫性甲状腺疾病中55%为Graves病。
  • 发生自身免疫性甲状腺疾病者扩展残疾状态量表评分降低且无复发生存率更高。

核心结论

  • Graves病是多发性硬化患者接受阿仑单抗后发生的最常见自身免疫性甲状腺疾病形式。
  • 本研究提示发生自身免疫性甲状腺疾病的多发性硬化患者对阿仑单抗可能有更好的反应,表现为残疾减轻和复发率降低。

研究设计与样本

  • 回顾性分析2012至2017年一家三级转诊中心126例接受阿仑单抗治疗的复发缓解型多发性硬化患者。

主要发现

  • 126例接受阿仑单抗治疗的患者中26%(33/126,25例女性,8例男性)发生自身免疫性甲状腺疾病,其中55%为Graves病。
  • 发生自身免疫性甲状腺疾病者扩展残疾状态量表评分较未发生者降低(中位数[四分位距];发生组:-0.25[-1至0.5] vs 未发生组:0[1-0],P=0.007)。
  • 多变量回归分析证实发生自身免疫性甲状腺疾病与扩展残疾状态量表评分改善独立相关(P=0.011)。
  • 发生自身免疫性甲状腺疾病者接受阿仑单抗后无复发生存率更高(P=0.023)。
  • 两组接受阿仑单抗后新发局灶性T2病灶数和对比增强磁共振成像病灶数无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Alemtuzumab is an anti-CD52 monoclonal antibody used in the treatment of relapsing-remitting multiple sclerosis (MS). Between 20% and 40% of alemtuzumab-treated MS patients develop autoimmune thyroid disease (AITD) as a side effect. OBJECTIVE: The objective of this work is to determine whether MS disease progression following alemtuzumab treatment differs in patients who develop AITD compared to those who do not. DESIGN, SETTING, AND PATIENTS: A retrospective analysis of 126 patients with relapsing-remitting MS receiving alemtuzumab from 2012 to 2017 was conducted at a tertiary referral center. MAIN OUTCOME MEASURES: Thyroid status, new relapses, Expanded Disability Status Scale (EDSS) score change, and disability progression following alemtuzumab were evaluated. RESULTS: Twenty-six percent (33 out of 126, 25 female, 8 male) of alemtuzumab-treated patients developed AITD, 55% of which was Graves disease. EDSS score following alemtuzumab was reduced in patients who developed AITD compared to those who did not (median [interquartile range]; AITD: -0.25 [-1 to 0.5] vs non-AITD: 0 [1-0]. P = .007]. Multivariable regression analysis confirmed that the development of AITD was independently associated with EDSS score improvement (P = .011). Moreover, AITD patients had higher relapse-free survival following alemtuzumab (P = .023). There was no difference in the number of new focal T2 lesions and contrast-enhancing magnetic resonance imaging lesions developed following alemtuzumab between the 2 groups. CONCLUSION: Graves disease was the most common form of AITD developed by MS patients following alemtuzumab. This study suggests that MS patients who develop AITD may have an improved response to alemtuzumab, as measured by reduced disability and lower relapse rate.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Sovetkina A, Nadir R, Scalfari A, et al. Development of Autoimmune Thyroid Disease in Multiple Sclerosis Patients Post-Alemtuzumab Improves Treatment Response. J Clin Endocrinol Metab. 2020. PMID: 32667988. doi:10.1210/clinem/dgaa453

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。